Vedolizumab for refractory ulcerative colitis in pre-pubescent children

Document first published:: 9 July 2020
Page updated:: 22 July 2020
Topic:: Commissioning, Medicine, Specialised commissioning
Publication type:: Policy or strategy, Report

Document

$Clinical commissioning policy: Vedolizumab for refractory ulcerative colitis in pre-pubescent children$

Clinical commissioning policy: Vedolizumab for refractory ulcerative colitis in pre-pubescent children

PDF
132 KB
7 pages

Document

$Clinical panel report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children$

Clinical panel report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children

PDF
23 KB
2 pages

Document

$CPAG summary report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children$

CPAG summary report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children

PDF
67 KB
7 pages

Document

$Evidence report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children$

Evidence report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children

PDF
23 KB
3 pages

Document

$Evidence review: Vedolizumab for refractory ulcerative colitis in pre-pubescent children$

Evidence review: Vedolizumab for refractory ulcerative colitis in pre-pubescent children

PDF
300 KB
30 pages

Document

$Public consultation report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children$

Public consultation report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children

PDF
33 KB
2 pages

Document

$Public engagement report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children$

Public engagement report: Vedolizumab for refractory ulcerative colitis in pre-pubescent children

PDF
38 KB
3 pages